At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 188 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Trial Of Pf-00299804 Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen
In Brief
A Phase 2 clinical trial evaluating Erlotinib and PF-00299804 for Non-small Cell Lung Cancer. Completed, enrolled 188 participants across 59 sites in 12 countries.
Detailed Summary
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesAustralia, Brazil, Canada, Hong Kong, Poland, Puerto Rico, Singapore, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartNov 2008
Primary CompletionOct 2010
Study CompletionAug 2014
TodayJul 2026
First PostedOct 8, 2008
Enrollment StartNov 1, 2008
Primary CompletionOct 1, 2010
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.7 years ago
Interventions
Erlotinibdrug
Continuous oral dosing at 150 mg daily.
PF-00299804drug
Continuous oral dosing at 45mg daily